Close Menu

NEW YORK (GenomeWeb) – Sophia Genetics said today that it has closed on a $77 million Series E round of venture capital, led by new investor Generation Investment Management, with participation from Idinvest Partners and previous Sophia equity backers Balderton Capital and Alychlo.

Sophia, which now has co-headquarters in Boston and Lausanne, Switzerland, said that it will apply much of the new funding to expand its US presence by growing its workforce and marketing to more American hospitals.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.